Within 1 year, centers in every state in Australia were performing 68Ga-PSMA PET/CT and in less than 4 years, this form of targeted molecular imaging is not only being incorporated into routine clinical management of prostate cancer patients serviced by 40 centers country-wide, but arguably has become the standard of care throughout Australia in the diagnosis, selective staging and monitoring of therapeutic response of prostate cancer. Here, FOLH1 is linked to prostate cancer.